chOphthalmol. 1965; 74: 217–221.212, 74:217-21. doi: 10.1001/archopht.1965.00970040219016.

7. Delp SL, Maloney W, et al. Biomechanics of the hip. *Clin Orthop Relat Res.* 1991;(272):18-24. PMID: 1914297.

8. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. *Lancet Neurol.* 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3.

9. Gorelick PB, Rosenberg M, Pagano RJ. Enhanced ptosis in Myasthenia Gravis. *Arch Neurol.* 1981;38(8):531. doi:10.1001/archneur.1981.00510080093017.

10. Horáková M, Voháňka S. Scales and questionnaires used in myasthenia gravis. *Neurol. praxi.* 2017;18(5):309-313. doi: 10.36290/neu.2017.035.

11. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Ann. Thorac. Surg.* 2000;70(1):327-34, doi: 10.1212/wnl.55.1.16.

12. Katzberg HD, Barnett C, Merkies ISJ, et al. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. *Muscle Nerve.* 2014; 49(5):661-5. doi: 10.1002/mus.23988.

13. Meisel A, Sacca F, Spillane J, et al. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. *Eur J Neurol.* 2024; 31(7):e16280. Epub 2024. doi: 10.1111/ene.16280.

14. Meisel A, Baggi F, Behin A, et al. Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal. *J. Neurol.* 2023;30(1):266-282. Epub 2022 Oct 7. doi: 10.1111/ene.15565.

15. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. *J Neurol.* 2023; 270(8):3862-3875. Epub 2023 Apr 27. doi: 10.1007/s00415-023-11699-x.

16. Mendoza M, Tran C, Bril V, et al. Patient-acceptable symptom states in myasthenia gravis. Epub. 2020; 95(12):e1617-e1628. doi: 10.1212/WNL.0000000000010574.

17. Metz HS, Scott AB, O'Meara DM. Saccadic Eye Movements in Myasthenia Gravis. *Arch Ophthalmol.* 1972;88(1):9-11. doi:10.1001/archopht.1972.01000030011003.

18. Motte J, Sgodzai M, Gold CS, et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. *Neuron.* 2024;112(11):1757-1763.e2. Epub 2024 May 1. doi: 10.1016/j.neuron.2024.04.014.

19. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. *Acta Myol.* 2007;26(1):5-10. PMID: 17915563. PMCID: PMC2949330.

20. Nowak RJ, Muppidi S, Beydoun SR, et al. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. *Front Neurol.* 2020:11:556104., eCollection 2020. doi: 10.3389/fneur.2020.556104.

21. Norwood F, Rawlings C, Nightingale P, et al. The effectiveness of the 'ice test' in the diagnosis of myasthenia gravis. *J Neurol Neurosurg Psychiatry.* 2007;78(5):622–623. doi: 10.1136/jnnp.2006.100537.

22. Osserman KE. Clinical aspects. In: Osserman KE, ed. Myasthenia gravis. New York. *NY: Grune & Straton.* 1958:79-80.

23. Shuey NH. Ocular myasthenia gravis: a review and practical guide for clinicians. *Clin Exp Optom.* 2022;105(2):205-213. doi: 10.1080/08164622.2022.2029683. Epub 2022 Feb 14.

24. Thomsen JLS, Andersen H. Outcome Meaures in Clnical Trials of Patients With Myasthenia Gravis. *Frontiers in Neurology.* 2020;11:596382. doi: 10.3389/fneur.2020.596382.

25. Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorder. *J Rheumatol.* 2007;34(5):1188–1193. PMCID: PMC2760122

26. Twork S, Wiesmeth S, Klewer J, et al. Quality of life and life satisfaction in patients with myasthenia gravis. *Nervenarzt.* 2012;83(4):452-9. doi: 10.1007/s00115-011-3386-3.

27. Uzawa A., Ozawa Y, Yasuda M, et al. Minimal symptom expression achievement over time in generalized myasthenia gravis. *Acta neurol Belg.* 2023;123(3):979-982. doi: 10.1007/s13760-022-02162-1.

28. Vissing J, Jacob S, Fujita KP, et al. Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. *J Neurol.* 2020; 267(7):1991-2001. Epub 2020 Mar 18. doi: 10.1007/s00415-020-09770-y.

29. Weindl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. *Ther Adv Neurol Disord.* 2023:16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023.

30. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *N Engl J Med.* 2016;375:511-522. doi: 10.1056/NEJMoa1602489.

Právě jste dokončili studium medicíny?

Máme pro vás odborný kongres zcela zdarma.



SOLEN MEDICAL EDUCATION